CHAOSTOCOSMOS

Friday, 21 March 2014

Rejected Twice, Potential Chronic Fatigue Syndrome Drug Still Moving Forward

Rejected Twice, Potential Chronic Fatigue Syndrome Drug Still Moving Forward: This week, Hemispherx Biopharma Inc. is taking part in a presentation at the 11th Biennial International Research and Clinical Conference called "Differential Exercise Responses to Ritnatolimod [Ampligen] Exhibited by Patients with Severe Chronic Fatigue Syndrome." It'll detail a Phase III prospective, double-blind, randomized, placebo-controlled trial looking at fatigue and post-exertional malaise.

No comments:

Related Posts Plugin for WordPress, Blogger...
^ Top